Eli Lilly

Lilly CEO John Lechleiter

10. Eli Lilly
2013 revenue: $23.113 billion
2012 revenue: $22.603 billion

Lilly ($LLY) may have moved into the Top 10 this year after failing to make the cut in 2012. But that doesn't mean 2013 was a knockout year for the Indianapolis-based drugmaker. On the contrary, it marked the second full year affected by the patent loss of blockbuster antipsychotic Zyprexa. Sales of the drug fell by 30% to $1.7 billion as it continued to drag down the company's full-year revenue, which still sits more than $1 billion below pre-patent-cliff levels.

Now, Lilly is up against a similar situation with leading seller Cymbalta, which fell prey to generic competition in December. Copycats dragged down the antidepressant's fourth-quarter sales by 38%, though the blow was not as bad as analysts had expected. And Cymbalta had most of the year to rack up megablockbuster sales, netting $5.1 billion.

A host of other blockbusters helped make up Lilly's 2013 sales tally, with second-best-seller Alimta, a lung cancer med, contributing $2.7 billion. Diabetes treatment Humalog was not far behind, grabbing another $2.6 billion for the drugmaker, with revenues swelling 9% over the previous year.

A few of Lilly's drugs grew even faster, hitting double-digit sales growth, with blockbuster Cialis among them. The erectile dysfunction treatment saw revenue gains of 12%, bringing its yearlong haul to $2.2 billion. And rising even faster was Strattera, an ADHD treatment that chipped in $709.2 million to log a 14% sales expansion. Lilly CEO John Lechleiter is promising that Lilly R&D will deliver multiple new drugs a year for the next several years to bring the company back. But it has promised that before, and since 2009 it has nailed only one actual new drug approval.

-- Carly Helfand (email | Twitter)

For more:
Lilly surprises on revenue even as Cymbalta sinks
Lilly CEO Lechleiter predicts big things after its 'most financially challenging year'
Lilly admits 2014 sales won't hit $20B, but sticks to $3B profits target
Eli Lilly expects no clarity on Alimta monopoly till 2014

Eli Lilly
Read more on

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.